Moderna received $50 million from CEPI to develop an mRNA Ebola vaccine targeting the Bundibugyo strain, amid a severe outbreak in DRC with over 1,000 cases and 241 deaths.
<p>The global health organization Coalition for Epidemic Preparedness Innovations (CEPI) <a href="https://cepi.net/cepi-fast-tracks-three-bundibugyo-ebolavirus-vaccine-candidates">announced Monday</a> that it will "urgently accelerate development" of three vaccine candidates against Bundibugyo ebolavirus (BDBV), pledging a little over $60 million in the effort to extinguish an outbreak currently raging out of control in the Democratic Republic of the Congo.</p>
<p>Under the plans, CEPI has committed up to $50 million to US-based Moderna for preclinical development and Phase 1 clinical testing of its mRNA-based BDBV vaccine candidate. The funding will simultaneously allow the company to ramp up manufacturing capabilities and ready large-scale Phase 2/3 trials in the event the vaccine makes it through early testing. The vaccine will use Moderna's mRNA vaccine platform that allowed for rapid development of a COVID-19 vaccine during the pandemic.</p>
<p>"[W]e believe our mRNA platform can play an important role in responding rapidly to emerging infectious disease threats," Moderna CEO Stéphane Bancel said in <a href="https://feeds.issuerdirect.com/news-release.html?newsid=4934808867799048&symbol=MRNA">a statement Monday</a>. " We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."</p><p><a href="https://arstechnica.com/health/2026/06/moderna-gets-50-million-to-develop-mrna-ebola-vaccine-against-bundibugyo/">Read full article</a></p>
<p><a href="https://arstechnica.com/health/2026/06/moderna-gets-50-million-to-develop-mrna-ebola-vaccine-against-bundibugyo/#comments">Comments</a></p>
# Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo
Source: [https://arstechnica.com/health/2026/06/moderna-gets-50-million-to-develop-mrna-ebola-vaccine-against-bundibugyo/](https://arstechnica.com/health/2026/06/moderna-gets-50-million-to-develop-mrna-ebola-vaccine-against-bundibugyo/)
## Raging outbreak
CEPI will also provide $3\.2 million to the International AIDS Vaccine Initiative, which is developing a vaccine that uses the same technology as Merck’s approved Ebola vaccine, Ervebo, which targets the more common Zaire ebolavirus strain\.
Last, the CEPI is committing $8\.6 million to the University of Oxford and Serum Institute of India, which is using its adenovirus\-based vaccine platform, as it did for its COVID\-19 vaccine during the pandemic\.
There are two licensed vaccines against Ebola disease currently, including Ervebo and Zabdeno/Mvabea by Johnson & Johnson\. Both vaccines target the Zaire strain, which has caused most of the large outbreaks to date, followed by the Sudan strain\. The current outbreak is only the third driven by the Bundibugyo strain\. As such, there are currently no licensed therapeutics or vaccines against it\.
The lack of medical interventions is one of the challenges facing health officials responding to the outbreak\. Detection of the outbreak was delayed, allowing the virus to spread out of control\. Disease is also spreading in an area of DRC with armed conflict, large population mobility, and significant need for humanitarian assistance\.
As of Friday, the World Health Organization reported 1,041 cases \(135 confirmed, 906 suspected\) and 241 deaths \(18 confirmed, 223 suspected\) in the outbreak\.
Moderna partners with OpenAI to deploy ChatGPT Enterprise across thousands of employees, implementing a comprehensive AI transformation strategy to accelerate mRNA medicine development and bring 15 new products to market within 5 years.
Funding cuts by the Trump administration have halted CREID research centers from responding to the Ebola outbreak in the DRC, hindering diagnostic and surveillance efforts.
This article details the development of CodonRoBERTa, a language model trained across 25 species for mRNA codon optimization, highlighting a cost-effective pipeline that includes protein folding and sequence design.
Demis Hassabis, co-founder of Google DeepMind, announces $2.1 billion in funding for Isomorphic Labs to use AI to cure all diseases by accelerating drug discovery.
MIT Technology Review's newsletter covers a new low-cost lithium extraction method using weak acid, a concerning Ebola outbreak in the DRC, and an opinion piece on Pope Leo XIV's AI encyclical urging ethical action.